DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

Author(s):

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP: 4.Examining 3-Year Update Data from the CASPIAN Trial

EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

Now Viewing

EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

EP: 12.Examining Key Data from DAREON-8

EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

DELLphi-301 Phase 2 Clinical Trial of Tarlatamab
- Please share your insights on the importance of ORR and DoR in patients with ES-SCLC who have relapsed or who are refractory to platinum-based chemotherapy.
- At the community practice level, does 90 days continue to mark platinum sensitivity status among patients with ES SCLC?
- What other factors contribute to the definition of treatment resistance in this patient subgroup?
- How clinically meaningful is a median OS of 14 months and a DoR of between 6 and 9 months in patients with relapsed or refractory ES SCLC?
- How do you weigh the risk-benefit ratio of treatment with tarlatamab in relapsed or refractory ES SCLC?
- To what degree might a Black Box warning on risk of CRS and ICANS impact ready adoption of this new therapy by community oncologists for their patients with progressive ES SCLC?
- Given that no fatal CRS or ICANS events were reported with the 10 mg dose and only one dose interruption was reported in Part 1 and 2 of the published Phase II study report, what is the potential to reduce patient monitoring time between bimonthly infusions of tarlatamab?